Literature DB >> 14512197

Studies of the interaction of potassium(I), calcium(II), magnesium(II), and copper(II) with cyclosporin A.

Rodney M Cusack1, Lisbeth Grøndahl, David P Fairlie, Graeme R Hanson, Lawrence R Gahan.   

Abstract

Metal ion binding properties of the immunosuppressant drug cyclosporin A have been investigated. Complexation studies in acetonitrile solution using 1H NMR and CD spectroscopy yielded 1:1 metal-peptide binding constants (log(10)K) for potassium(I), <1, magnesium(II), 4.8+/-0.2, and calcium(II), 5.0+/-1.0. The interaction of copper(II) with cyclosporin A in methanol was investigated with UV/visible and electron paramagnetic resonance (EPR) spectroscopy. No complexation of copper(II) was observed in neutral solution. In the presence of base, monomeric copper(II) complexes were detected. These results support the possibility that cyclosporin A has ionophoric properties for biologically important essential metal ions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14512197     DOI: 10.1016/s0162-0134(03)00288-5

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  3 in total

1.  1H and 13C-NMR and molecular dynamics studies of cyclosporin a interacting with magnesium(II) or cerium(III) in acetonitrile. Conformational changes and cis-trans conversion of peptide bonds.

Authors:  Francesca Bernardi; Elena Gaggelli; Elena Molteni; Elena Porciatti; Daniela Valensin; Gianni Valensin
Journal:  Biophys J       Date:  2005-11-18       Impact factor: 4.033

2.  Cyclosporin A: Conformational Complexity and Chameleonicity.

Authors:  Satoshi Ono; Matthew R Naylor; Chad E Townsend; Chieko Okumura; Okimasa Okada; Hsiau-Wei Lee; R Scott Lokey
Journal:  J Chem Inf Model       Date:  2021-10-21       Impact factor: 6.162

Review 3.  Ribosomal peptide natural products: bridging the ribosomal and nonribosomal worlds.

Authors:  John A McIntosh; Mohamed S Donia; Eric W Schmidt
Journal:  Nat Prod Rep       Date:  2009-04       Impact factor: 13.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.